Abstract: In a method for testing the visual field of a patient especially the central visual field, stereoscopic or binocularly displaced fixation images are presented under computer control to the respective eyes of the patient. In addition, a series of test images viewable by only one of the patient's eyes is generated under the control of the computer. The fixation images, one for each eye, are presented on two separate electronic displays, while the test images may be produced on a third display member different from the electronic displays. The computer is programmed to precisely determine a boundary between points corresponding to unseen test images and points corresponding to seen test images, by automatically testing additional points in a region located about the curve and between points corresponding to unseen test images and points corresponding to seen test images.

Abstract: In a method for testing the visual field of a patient especially the central visual field, stereoscopic or binocularly displaced fixation images are presented under computer control to the respective eyes of the patient. In addition, a series of test images viewable by only one of the patient's eyes is generated under the control of the computer. The fixation images, one for each eye, are presented on two separate electronic displays, while the test images may be produced on a third display member different from the electronic displays. The computer is programmed to precisely determine a boundary between points corresponding to unseen test images and points corresponding to seen test images, by automatically testing additional points in a region located about the curve and between points corresponding to unseen test images and points corresponding to seen test images.

Abstract: A topical drug application for the alleviation of kerato-conjunctivitis sicca (dry eye syndrome) is comprised of a solution of 17-.beta.-estradiol suspended or dissolved in a vehicle, and the method of preparation and application of the same. In the preferred embodiments, 17-.beta.-estradiol is in a lipid vehicle or 17-.beta.-estradiol 3-phosphate disodium dissolved in an aqueous vehicle having a pH of between about 6 to about 8. This invention may also be useful in treating other conditions where KCS may occur, such as post-operative corneal transplant patients and patients who cannot receive replacement estrogen therapy.

Abstract: A topical drug application for the alleviation of keratoconjunctivitis sicca (dry eye syndrome) is comprised of a solution of sex steroids or their derivatives suspended or dissolved in a vehicle, and the method of preparation and application of the same. In the preferred embodiments, the sex steroid consists essentially of conjugated estrogen in a lipid vehicle or a derivative of estrogen known as 17 beta-Estradiol 3-phosphate disodium dissolved in an aqueous vehicle having a pH of between 6 and 8.

Abstract: A topical drug application for the alleviation of kerato-conjunctivitis sicca (dry eye syndrome) is comprised of a solution of sex steroids or their derivatives suspended or dissolved in a vehicle, and the method of preparation and application of the same. In the preferred embodiments, the sex steroid consists essentially of conjugated estrogen in a lipid vehicle or a derivative of estrogen known as 17 beta-Estradiol 3-phosphate disodium dissolved in an aqueous vehicle having a pH of between 6 and 8.